The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
Open accessAbstract
BACKGROUND: Advanced biliary tract carcinomas (BTCs) have poor prognosis and limited therapeutic options. Therefore, it is crucial to combine standard therapies with molecular targeting. In this study EGFR, HER2, and their molecular transducers were analysed in terms of mutations, amplifications and over-expression in a BTC case series. Furthermore, we tested the efficacy of drugs targeting these molecules, as single agents or in combination with gemcitabine, the standard therapeutic agent against BTC. METHODS: Immunohistochemistry, FISH and mutational analysis were performed on 49 BTC samples of intrahepatic (ICCs), extrahepatic (ECCs), and gallbladder (GBCs) origin. The effect on cell proliferation of different EGFR/HER2 pathway inhibitors as single agents or in combination with gemcitabine was investigated on BTC cell lines. Western blot analyses were performed to investigate molecular mechanisms of targeted drugs. RESULTS: EGFR is expressed in 100% of ICCs, 52.6% of ECCs, and in 38.5% of GBCs. P-MAPK and p-Akt are highly expressed in ICCs (>58% of samples), and to a lower extent in ECCs and GBCs (<46%), indicating EGFR pathway activation. HER2 is overexpressed in 10% of GBCs (with genomic amplification), and 26.3% of ECCs (half of which has genomic amplification). EGFR or its signal transducers are mutated in 26.5% of cases: 4 samples bear mutations of PI3K (8.2%), 3 cases (6.1%) in K-RAS, 4 (8.2%) in B-RAF, and 2 cases (4.1%) in PTEN, but no loss of PTEN expression is detected. EGI-1 cell line is highly sensitive to gemcitabine, TFK1 and TGBC1-TKB cell lines are responsive and HuH28 cell line is resistant. In EGI-1 cells, combination with gefitinib further increases the antiproliferative effect of gemcitabine. In TFK1 and TGBC1-TKB cells, the efficacy of gemcitabine is increased with addiction of sorafenib and everolimus. In TGBC1-TKB cells, lapatinib also has a synergic effect with gemcitabine. HuH28 becomes responsive if treated in combination with erlotinib. Moreover, HuH28 cells are sensitive to lapatinib as a single agent. Molecular mechanisms were confirmed by western blot analysis. CONCLUSION: These data demonstrate that EGFR and HER2 pathways are suitable therapeutic targets for BTCs. The combination of gemcitabine with drugs targeting these pathways gives encouraging results and further clinical studies could be warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Cited by
Gallbladder cancer: epidemiology and outcome
Shaffer, E., & Hundal, R. (2014) · Clinical Epidemiology · doi:10.2147/clep.s37357 · Cited by 1,089
Li, M., Zhang, Z., Li, X., Ye, J., Wu, X., Tan, Z., Liu, C., Shen, B., Wang, X.-A., Wu, W., et al. (2014) · Nature Genetics · doi:10.1038/ng.3030 · Cited by 443
Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update
Sharma, A., Sharma, K. L., Gupta, A., Yadav, A., & Kumar, A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i22.3978 · Cited by 424
Malka, D., Cervera, P., Foulon, S., Trarbach, T., de la Fouchardière, C., Boucher, E., Fartoux, L., Faivre, S., Blanc, J.-F., Viret, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70212-8 · Cited by 408
Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma
Esnaola, N. F., Meyer, J. E., Karachristos, A., Maranki, J. L., Camp, E. R., & Denlinger, C. S. (2016) · Cancer · doi:10.1002/cncr.29692 · Cited by 296
Metadata
- Authors
- Pignochino, Y., Sarotto, I., Peraldo-Neia, C., Penachioni, J. Y., Cavalloni, G., Migliardi, G., Casorzo, L., Chiorino, G., Risio, M., Bardelli, A., Aglietta, M., & Leone, F.
- Venue
- BMC Cancer
- Published
- 2010-11-18
- Volume
- 10
- Issue
- 1
- Pages
- 631-631
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W1981051246
- Cited by
- 173
- References
- 2
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. https://app.cochat.ai/papers/10.1186/1471-2407-10-631
- The paper
- Pignochino, Y., Sarotto, I., Peraldo-Neia, C., Penachioni, J. Y., Cavalloni, G., Migliardi, G., Casorzo, L., Chiorino, G., Risio, M., Bardelli, A., Aglietta, M., & Leone, F. (2010). Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. https://doi.org/10.1186/1471-2407-10-631
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.